Gallium-68 NOTA hGZP
Alternative Names: [68Ga]-NOTA-hGZP; CSB-111Latest Information Update: 28 Jul 2023
At a glance
- Originator Cytosite Bio; Massachusetts General Hospital; University of Alabama at Birmingham
- Developer Cytosite Bio; Massachusetts General Hospital
- Class Diagnostic agents; Imaging agents
- Mechanism of Action Ionising radiation emitters; Positron-emission tomography enhancers
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I Cancer; Malignant melanoma; Non-small cell lung cancer
Most Recent Events
- 28 Jul 2023 No recent reports of development identified for phase-I development in Malignant-melanoma(Diagnosis) in USA (Parenteral, Injection)
- 28 Jul 2023 No recent reports of development identified for phase-I development in Non-small-cell-lung-cancer(Diagnosis) in USA (Parenteral, Injection)
- 20 May 2023 Cytosite Biopharma completes a phase-I clinical trial in Cancer (In volunteers) in USA (IV) (NCT05285696)